相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells
Anja Berger et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
The BH3-only protein BimL overrides Bcl-2-mediated apoptosis resistance in melanoma cells
Michael Ploetz et al.
CANCER LETTERS (2013)
The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
David Wroblewski et al.
CARCINOGENESIS (2013)
Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells
Denis Selimovic et al.
CELLULAR SIGNALLING (2013)
BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells
Ayano Watanabe et al.
EXPERIMENTAL DERMATOLOGY (2013)
Bcl-2 antagonists: a proof of concept for CLL therapy
Kumudha Balakrishnan et al.
INVESTIGATIONAL NEW DRUGS (2013)
BH3 Mimetics: Status of the Field and New Developments
Christian Billard
MOLECULAR CANCER THERAPEUTICS (2013)
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Rizwan Haq et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells
Daniela Beck et al.
SCIENCE SIGNALING (2013)
ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis
S-A Quast et al.
CELL DEATH & DISEASE (2013)
Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax
A. Berger et al.
CELL DEATH & DISEASE (2013)
Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Mariusz L. Hartman et al.
Anti-Cancer Agents in Medicinal Chemistry (2012)
Disruption of the VDAC2-Bak interaction by Bcl-xS mediates efficient induction of apoptosis in melanoma cells
M. Ploetz et al.
CELL DEATH AND DIFFERENTIATION (2012)
Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
Keryn M. Lucas et al.
CLINICAL CANCER RESEARCH (2012)
Molecular Determinants of Bim(BH3) Peptide Binding to Pro-Survival Proteins
Laura Delgado-Soler et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Targeting IAP proteins for therapeutic intervention in cancer
Simone Fulda et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
Daniela Senft et al.
PLOS ONE (2012)
General Sensitization of Melanoma Cells for TRAIL-Induced Apoptosis by the Potassium Channel Inhibitor TRAM-34 Depends on Release of SMAC
Sandra-Annika Quast et al.
PLOS ONE (2012)
Mutual Regulation of Bcl-2 Proteins Independent of the BH3 Domain as Shown by the BH3-Lacking Protein Bcl-xAK
Michael Ploetz et al.
PLOS ONE (2012)
Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress
K. H. Tay et al.
CELL DEATH & DISEASE (2012)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum
Caterina Longo et al.
EXPERIMENTAL DERMATOLOGY (2011)
Towards new therapeutic approaches for malignant melanoma
Ivan Pacheco et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
Efficient Melanoma Cell Killing and Reduced Melanoma Growth in Mice by a Selective Replicating Adenovirus Armed with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
Lothar F. Fecker et al.
HUMAN GENE THERAPY (2011)
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey J. Wallin et al.
MOLECULAR CANCER THERAPEUTICS (2011)
New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue
Jeannine C. Franke et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
Gajanan S. Inamdar et al.
BIOCHEMICAL PHARMACOLOGY (2010)
TRAIL: A Sword for Killing Tumors
S. Wang
CURRENT MEDICINAL CHEMISTRY (2010)
Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus
Lothar F. Fecker et al.
EXPERIMENTAL DERMATOLOGY (2010)
Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma
Bernhard Gillissen et al.
JOURNAL OF CELL BIOLOGY (2010)
The BCL-2 Family Reunion
Jerry E. Chipuk et al.
MOLECULAR CELL (2010)
Mitochondria and cell death: outer membrane permeabilization and beyond
Stephen W. G. Tait et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Phosphorylation of Puma modulates its apoptotic function by regulating protein stability
M. Fricker et al.
CELL DEATH & DISEASE (2010)
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
C. C. Jiang et al.
CELL DEATH & DISEASE (2010)
Small molecules and targeted therapies in distant metastatic disease
P. Hersey et al.
ANNALS OF ONCOLOGY (2009)
Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma
Matthew W. VanBrocklin et al.
CANCER RESEARCH (2009)
Melanoma epidemiology and trends
Claus Garbe et al.
CLINICS IN DERMATOLOGY (2009)
Bim-targeted cancer therapy: A link between drug action and underlying molecular changes
Toru Akiyama et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells
Bi-ke Zhu et al.
ANTI-CANCER DRUGS (2008)
Apoptosis induction by Bcl-2 proteins independent of the BH3 domain
Amir M. Hossini et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Bim expression is reduced in human cutaneous melanomas
Derek L. Dai et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes
Changchun Xiao et al.
NATURE IMMUNOLOGY (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Bmf and Bmf in tissue homeostasis and malignant disease
J. D. Pinon et al.
ONCOGENE (2008)
Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
Robert A. Cartlidge et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma
Juergen Eberle et al.
EXPERIMENTAL DERMATOLOGY (2008)
Overcoming apoptosis deficiency of melanoma - Hope for new therapeutic approaches
Juergen Eberle et al.
DRUG RESISTANCE UPDATES (2007)
Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma:: evidence for contribution to apoptosis resistance
N. Zantl et al.
ONCOGENE (2007)
Bim and the pro-survival bcl-2 proteins - Opposites attract, ERK repels
Katherine E. Ewings et al.
CELL CYCLE (2007)
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins
K. G. Wolter et al.
CELL DEATH AND DIFFERENTIATION (2007)
Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1
Yu Fang Wang et al.
CLINICAL CANCER RESEARCH (2007)
Life and death in peripheral T cells
Peter H. Krammer et al.
NATURE REVIEWS IMMUNOLOGY (2007)
BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins
Arnim Weber et al.
JOURNAL OF CELL BIOLOGY (2007)
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4
B. M. Kurbanov et al.
ONCOGENE (2007)
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Liqing Zhuang et al.
MODERN PATHOLOGY (2007)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis
Lothar F. Fecker et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells
Y Yamamura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
How the Bcl-2 family of proteins interact to regulate apoptosis
MF van Delft et al.
CELL RESEARCH (2006)
BH3-only proteins Puma and Bim are rate-limiting for γ-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo
M Erlacher et al.
BLOOD (2005)
Life in the balance: how BH3-only proteins induce apoptosis
SN Willis et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik
M Oppermann et al.
ONCOGENE (2005)
Differential regulation of noxa in normal Melanocytes and melanoma cells by proteasome inhibition:: Therapeutic implications
Y Fernández et al.
CANCER RESEARCH (2005)
c-Myc-regulated microRNAs modulate E2F1 expression
KA O'Donnell et al.
NATURE (2005)
Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications
C Akgul et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Molecular mechanisms of caspase regulation during apoptosis
SJ Riedl et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
FoxO3a transcriptional regulation of bim controls apoptosis in paclitaxel-treated breast cancer cell lines
A Sunters et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa
A Villunger et al.
SCIENCE (2003)
Apoptosis: A link between cancer genetics and chemotherapy
RW Johnstone et al.
CELL (2002)
PUMA, a novel proapoptotic gene, is induced by p53
K Nakano et al.
MOLECULAR CELL (2001)
Phosphorylation of the pro-apoptotic protein BIK - Mapping of phosphorylation sites and effect on apoptosis
S Verma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c
SJ Korsmeyer et al.
CELL DEATH AND DIFFERENTIATION (2000)
Chemosensitisation of malignant melanoma by BCL2 antisense therapy
B Jansen et al.
LANCET (2000)
The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells
LA O'Reilly et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
